We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. Deeply rooted in science and innovation, our vision is to compassionately contribute to solving cancer.

HBM Healthcare Investments AG

HBM Partners

Cormorant Asset Management

SR One

Wellington Management

Novartis Venture Fund

OrbiMed

Pontifax

Samsung Securities

Medicxi

3B Future Health Fund

SICAR

Windham Venture Partners

Fore Biotherapeutics

We are excited to be presenting a poster at #AACR24 next week:
Abstract #:4609 “Plixorafenib (plixo) synergizes with MEK inhibitors (MEKi) in MAPK pathway inhibition in BRAF V600 and non V600 alterations, with higher potency compared to early generation BRAFi and pan-RAFi”
https://lnkd.in/epDjVhJE
Members of the team, Drs Stacie Shepherd, Ted Everson, and Ping J., look forward to connecting with you there!

Today, FORE Bio named William R. Hinshaw as Chief Executive Officer. Bill’s extensive leadership experience in biotech and pharma companies, including the approvals of multiple oncology products and indications while at Novartis, will be key as FORE advances its ongoing Global Phase 2 FORTE study of plixorafenib.
Click here to read the full release https://lnkd.in/eaaZ7yfd

Today, FORE Bio announced that the Company will participate in the following investor conferences: 
·        Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will take place on Wednesday, February 14 from 8:00 a.m. – 8:30 a.m. ET.
·        Evercore ISI’s 2024 Emerging Private Biotech Conference. The presentation will take place on Wednesday, February 28 from 1:05 p.m. – 1:35 p.m. ET.
Please email Forebio@argotpartners.com to request a 1:1 meeting with management.

We wish our team and our partners around the world a very Happy Holiday season and a peaceful and prosperous New Year. #TeamFore

FORE Bio will be presenting at the 2023 RBC Capital Markets Private Company Conference on Thursday, December 14 at 8 a.m. ET. The company will also be hosting 1-on-1 meetings. Please email forebio@argotpartners.com to request a meeting.
https://lnkd.in/gST_nu7h

ArriVent is a precision oncology company focused on developing targeted cancer therapies.

ArriVent

Elucida Oncology is dedicated to developing precision oncology treatments for patients with unaddressed mutations in well-established oncology targets.

Elucida Oncology

Erasca is a precision oncology company that utilizes functional genomics to develop personalized cancer therapies.

Erasca

NexImmune is a biotechnology company specializing in precision oncology and immunotherapy.

NexImmune

Pyxis Oncology is dedicated to developing precision oncology treatments targeting specific tumor mutations.

Pyxis Oncology

Abcuro is a biotechnology company focused on precision oncology and developing targeted cancer therapies.

Abcuro

Alterome Therapeutics is dedicated to developing precision oncology treatments for patients with unaddressed mutations in well-established oncology targets.

Alterome Therapeutics

NextCure is a biotechnology company specializing in precision oncology and immunotherapy.

NextCure

Fore Bio is a next-generation precision oncology company that utilizes its functional genomics platform to hyper-target therapies to unaddressed tumor mutations, providing patients with few therapeutic alternatives with new treatments tailored to them.

Senior Director

Director

Senior Project Manager

Compliance Director

EHS Manager / Process Engineer

Sr. Director, Project/Program Management at Fore Bio

Rekha Sheth

Director Of Bioinformatics

Eden Goldfarb

Sr Director, Statistics

Director Biostatistics

Associate Director of Biostatistics

Biostatistician

Kongming W.

Sr. Director, Clinical Operations

Director of Clinical Operations

Strategy Insights & Planning Consultant

Clinical Research Manager

Sr. Product Manager, Hematology Marketing

Senior Clinical Research Scientist

Clinical Research Associate

Clinical Safety Associate

Sr. Director, Clinical Operations at Fore Biotherapeutics

Jessica Rine

Chief Medical Officer

SVP, Clinical Development

Vice President, Oncology

Senior Medical Director

Medical Director

Associate Medical Director

Fellow, Pediatric Endocrinology

Chief Medical Officer at Fore Biotherapeutics

Stacie Shepherd

Director QA-CMC

Associate Director QA-CMC

Associate Director Quality

Senior Manager, Quality Assurance

Sr. QA Specialist

QA Manager

Betty Metellus-Boutros

Chief Executive Officer

President and CEO

Executive Vice President US Oncology

Region Head, NCE (Northern Central Europe), Novartis Oncology

Region Head, Group Emerging Markets, Novartis Group

Oncology Business Unit Head, Schering Laboratories

Sales Leadership

Marketing Leadership

CEO  at Fore Biotherapeutics

William Hinshaw

Chief Financial Officer

Board Member and Audit Committee

Managing Director - Healthcare Investment Banking

Senior Managing Director - Head of Life Sciences Investment Banking

Managing Director - Head of Life Sciences Investment Banking

Vice President - Healthcare Investment Banking

Founder and CEO

Chief Financial Officer | Board Member

Jeff Sacher

Sr Director Statistics at Fore Bio

Kongming Wang

Director, Analytical, CMC

Associate Director, CMC

Associate Director, Analytical, CMC

Senior Manager

Director, AR&D/QC

Principal Scientist

Senior. Scientist

Director, Analytical, CMC at ForeBio

Ravi Juneja

Associate Director

Sr. Clinical Trial Manager

Project Manager II

Clinical Project Manager

Project Manager, Peri and Post Approval Research Operations

Project Manager, Endpoint Adjudication

Assistant Project Manager

Project Leader

Senior Project Coordinator

Associate Director at FORE Biotherapeutics

Michael Paz

Director, Human Resources

Senior Human Resources Manager

HR Manager

Human Resources Manager

HR Generalist/ Office Manager

Operations Manager

Office Manager & Project Manager

Executive Assistant

Senior Parachute Rigger + Instructor

Activity Centre Manager and Instructor

Director, Human Resources at Fore Biotherapeutics

Marie Forbes

Executive Director, Translational Sciences

Sr. Director

Director, Translational Science

Associate Director, Translational Clinical Science, Oncology

Associate Director, Translational Biology

Sr. Scientist II

Sr. Scientist I

Ping J.

Executive Director, Medical Affairs

Independent Consultant

Senior Director, Medical Affairs

Senior Medical Director, TDR/EGFR

Medical Affairs Lead, Oncology

Director, Global and US Medical Affairs, Oncology

Associate Director, Worldwide Medical

Senior Manager, Scientific Communications, Oncology

Director, Medical Communications

Program Manager, Biotechnology and Pharmaceutical History and Policy

Executive Director, Medical Affairs at Fore Biotherapeutics

Ted Everson

Executive Director

Therapeutic Area Lead

Clinical Lead

Research Physician

Clinical Trial Lead

Therapeutic Research Associate

Irina Kline

Senior Director Quality Assurance

Associate Director, GCP QA/QC

Senior Clinical QA Manager

Senior Director, GCP Quality Assurance Professional

Francesca Kelvy

Director of Finance

Controller

Manager

Director of Finance at Fore Biotherapeutics

Bat-El Reuven

Senior Director of R&D

Project manager and senior scientist at FORE Biotherapeutics

Senior researcher and lab manager

Lecturer

Postdoctoral Fellow

Senior Director of R&D | Cancer research |  Translational science | Personalized medicine

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	May 4, 2024 6:00 AM	b7f6b99e
public peers	general	May 4, 2024 6:00 AM	4e31ca4b
news daily refresh	general	Jul 25, 2024 12:00 PM	6398d6e3
news processing daily refresh	general	May 21, 2024 2:46 AM	ff6bc9aa
news impact assignment daily	general
news processing basic	general	May 4, 2024 6:00 AM	ce18ca23
company summary	general
signals	general
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general
news basic	general	May 4, 2024 6:00 AM	70f69114
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
swot analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
customer profile	customers

BIO:FORE

Fore Bio